PMGC Holdings’ Northstrive Biosciences Executes Statement Of Work With Charles River To Conduct Analytical Characterization Supporting Development Of EL-22 And EL-32 Engineered Probiotic Programs
Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive
Northstrive hired a well-known lab to test two new medicines. This means the company is moving forward with its work on schedule.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.